An Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labelled GFT505 and Its 14C-Metabolites) and to Investigate the Metabolic Profile and Pharmacokinetics of GFT505

Trial Profile

An Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labelled GFT505 and Its 14C-Metabolites) and to Investigate the Metabolic Profile and Pharmacokinetics of GFT505

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Genfit
  • Most Recent Events

    • 28 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Mar 2015 Planned End Date changed from 1 Jun 2014 to 1 Apr 2015, according to ClinicalTrials.gov record.
    • 09 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top